https://scholars.lib.ntu.edu.tw/handle/123456789/634573
標題: | Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C | 作者: | SHIH-JER HSU Yu, Ming-Lung Su, Chien-Wei Peng, Cheng-Yuan Chien, Rong-Nan Lin, Hsien-Hong Lo, Gin-Ho Su, Wei-Wen Kuo, Hsing-Tao Hsu, Chao-Wei Yang, Sien-Sing Yang, Sheng-Shun Tseng, Kuan-Chiao Qin, Albert Huang, Yi-Wen Chuang, Wan-Long |
關鍵字: | Chronic hepatitis C; Genotype 2; Ribavirin; Ropeginterferon alfa-2b; Taiwan | 公開日期: | 三月-2021 | 卷: | 120 | 期: | 3 | 起(迄)頁: | 956 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to the 8 to 14 isomers of other on-market pegylated interferon products, allowing every-two-week injection with high tolerability. It received European Medicines Agency marketing authorization in 2019 and Taiwan Biologics License Applications Approval in 2020 for the treatment of polycythemia vera. This study aimed to evaluate the safety and efficacy of Ropeginterferon alfa-2b plus ribavirin in genotype 2 chronic hepatitis C (CHC) patients. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85092660681&doi=10.1016%2fj.jfma.2020.09.018&origin=inward&txGid=735eabc07467c963e6bc1115eab1c260 https://scholars.lib.ntu.edu.tw/handle/123456789/634573 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.09.018 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。